<DOC>
	<DOCNO>NCT02300922</DOCNO>
	<brief_summary>Phase I/II , Open-labeled , Prospective , Multi-center study Pretargeted Radioimmunotherapy metastatic colorectal cancer ractionated injection TF2 plus 90Y-IMP288 ( RITCOLON ) .</brief_summary>
	<brief_title>Pretargeted Radioimmunotherapy Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This study investigate pretargeted radioimmunotherapy ( pRAIT ) anti-carcinoembryonic antigen ( CEA ) TF2 bispecific monoclonal antibody ( BsMAb ) 90Y-IMP288 radio-labeled peptide . TF2 give week 3 successive week 75 mg/m2 per dose . IMP288 give 3 time , 1 day TF2 injection . IMP288 radio-labeled 111In ( image ) first injection 90Y ( therapy ) 2 subsequent injection .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Metastatic colorectal cancer failure standard therapy ( 5fluorouracil , irinotecan , oxaliplatin , antivascular endothelium growth factor , antiepidermal growth factor patient RAS wild type tumor ) . A previous line regorafenib require . 2 . Elevated CEA serum level prove CEA expression tumor tissue 3 . ≥ 18 year age , 4 . Given sign , write informed consent 5 . Existence least one measurable tumor lesion CT MRI time treatment , single lesion ≥ 8 cm diameter . 6 . At least 4 week recovery period major surgery , radiation , chemotherapy , total recovery acute toxicity associate prior treatment . 7 . Life expectancy ≥ 3 month , Karnofsky performance status ≥ 70 % 8 . Adequate hematology renal function hepatic function 9 . Patients childbearing potential must willing practice birth control study least 12 week treatment , woman childbearing potential must negative serum pregnancy test enter study Exclusion Criteria : 1 . Known central nervous system metastatic disease 2 . &gt; 25 % bone marrow involvement 3 . CEA plasma level &gt; 2,000 ng/mL 4 . Patients successfully treat nonmelanoma skin cancer carcinoma situ cervix eligible , patient prior malignancy must least 3year diseasefree interval . 5 . HIV positive , hepatitis Bantigen positive , hepatitis C positive patient 6 . Known autoimmune disease , 7 . Known history unstable angina , myocardial infarction , congestive heart failure present within 6 month clinically significant cardiac arrhythmia ( stable atrial fibrillation ) require antiarrhythmia therapy , know history clinical significant , active chronic obstructive pulmonary disease , moderate severe chronic respiratory illness present within 6 month 8 . Infection require intravenous antibiotic use within 1 week inclusion , 9 . Corticosteroids allow within 2 week study entry study except low dos ( i.e. , 20 mg/day prednisone equivalent ) treat nausea illness rheumatoid arthritis . 10 . Patients receive treatment contain nitrosourea compound enrol least 6 week end treatment . 11 . Known hypersensitivity murine antibody proteins 12 . Immunization TF2 patient already receive injection TF2 13 . Adult patient unable give inform consent intellectual impairment . 14 . Adult patient protect French law</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>